{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:50:09Z","timestamp":1794865809526,"version":"4.9.1"},"reference-count":50,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,3,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Sixty-four patients &lt; 20 years of age, investigated for a suspicion of Philadelphia-negative myeloproliferative disease (MPD), were retrospectively evaluated to characterize the different forms and to examine the treatments used and long-term outcome. JAK2 mutations, endogenous erythroid colony growth, and clonality were investigated in 51 children. Mutations of thrombopoietin, the thrombopoietin receptor (MPL), and the erythropoietin receptor and mutations of other genes involved in the pathogenesis of MPD were investigated in JAK2 wild-type patients. Based on our criteria for childhood MPD, we identified 34 patients with sporadic thrombocythemia (ST), 16 with hereditary thrombocytosis (HT), 11 with sporadic polycythemia (SP), and 3 with hereditary polycythemia (HP). JAK2V617F mutations were present in 47.5% of ST and in no HT. The MPLS505A mutation was detected in 15\/16 HT patients and in no ST (P &lt; .00001). The JAK2V617F mutation occurred in 27% of SP patients diagnosed according to the Polycythemia Vera Study Group or World Health Organization 2001 criteria. Children with ST received more cytoreductive drugs than those with HT (P = .0006). After a median follow-up of 124 months, no patient had developed leukemia or myelofibrosis and 5% had thrombosis; the miscarriage rate in thrombocythemic patients was 14%. The low complication rate in our population suggests that children with MPD may be managed by tailored approaches.<\/jats:p>","DOI":"10.1182\/blood-2011-08-371328","type":"journal-article","created":{"date-parts":[[2012,1,20]],"date-time":"2012-01-20T02:13:49Z","timestamp":1327025629000},"page":"2219-2227","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":76,"title":["Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome"],"prefix":"10.1182","volume":"119","author":[{"given":"Fiorina","family":"Giona","sequence":"first","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Teofili","sequence":"additional","affiliation":[{"name":"Departments of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Moleti","sequence":"additional","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Martini","sequence":"additional","affiliation":[{"name":"Pathology, Catholic University, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Palumbo","sequence":"additional","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Amendola","sequence":"additional","affiliation":[{"name":"Department of Hematology, San Carlo Hospital, Potenza, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriella","family":"Mazzucconi","sequence":"additional","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Testi","sequence":"additional","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Pignoloni","sequence":"additional","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia Maria","family":"Orlando","sequence":"additional","affiliation":[{"name":"GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto, Italian Group for Hematological Diseases in Adults) Foundation, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Capodimonti","sequence":"additional","affiliation":[{"name":"Departments of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Nanni","sequence":"additional","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Leone","sequence":"additional","affiliation":[{"name":"Departments of Hematology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Maria","family":"Larocca","sequence":"additional","affiliation":[{"name":"Pathology, Catholic University, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Fo\u00e0","sequence":"additional","affiliation":[{"name":"Department of Cellular Biotechnologies and Hematology, Sapienza University, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2019111808290905200_B1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1034\/j.1600-0609.2000.90236.x","article-title":"Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area.","volume":"65","author":"Jensen","year":"2000","journal-title":"Eur J Haematol"},{"issue":"3","key":"2019111808290905200_B2","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1046\/j.1365-2141.2000.02239-7.x","article-title":"Incidence of essential thrombocythaemia in children.","volume":"110","author":"Hasle","year":"2000","journal-title":"Br J Haematol"},{"issue":"7","key":"2019111808290905200_B3","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasm.","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"issue":"1","key":"2019111808290905200_B4","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloprolipherative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"issue":"4","key":"2019111808290905200_B5","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-2007-996107","article-title":"Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group.","volume":"23","author":"Michiels","year":"1997","journal-title":"Semin Thromb Hemost"},{"issue":"10","key":"2019111808290905200_B6","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1182\/blood-2006-04-014746","article-title":"Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative.","volume":"108","author":"Randi","year":"2006","journal-title":"Blood"},{"issue":"9","key":"2019111808290905200_B7","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1200\/JCO.2006.08.6884","article-title":"Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.","volume":"25","author":"Teofili","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111808290905200_B8","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1365-2141.2008.07220.x","article-title":"Clinical and molecular characterization of a prospectively collected cohort of children and adolescents with polycythaemia vera.","volume":"142","author":"Cario","year":"2008","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111808290905200_B9","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1182\/blood-2007-06-094276","article-title":"The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia.","volume":"110","author":"Teofili","year":"2007","journal-title":"Blood"},{"issue":"2","key":"2019111808290905200_B10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3324\/haematol.12002","article-title":"Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients?","volume":"93","author":"Teofili","year":"2008","journal-title":"Haematologica"},{"issue":"6","key":"2019111808290905200_B11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/ajh.21183","article-title":"Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and prospect of targeted therapy.","volume":"83","author":"Tefferi","year":"2008","journal-title":"Am J Hematol"},{"issue":"6","key":"2019111808290905200_B12","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia- negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111808290905200_B13","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/00043426-199909000-00005","article-title":"Essential thrombocythemia in children.","volume":"21","author":"Dror","year":"1999","journal-title":"J Pediatr Hematol Oncol"},{"issue":"11","key":"2019111808290905200_B14","first-page":"1306","article-title":"A long-term study of young patients with essential thrombocythemia treated with anagrelide.","volume":"89","author":"Mazzucconi","year":"2004","journal-title":"Haematologica"},{"issue":"4","key":"2019111808290905200_B15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1600-0609.2006.00719.x","article-title":"Long-term use of anagrelide in the treatment of children with essential thrombocythemia.","volume":"77","author":"Lackner","year":"2006","journal-title":"Eur J Haematol"},{"issue":"2","key":"2019111808290905200_B16","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4065\/81.2.159","article-title":"Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates and prognostic factors.","volume":"81","author":"Wolanskyj","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"2019111808290905200_B17","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/sj.leu.2404693","article-title":"Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients.","volume":"21","author":"Alvarez-Larr\u00e1n","year":"2007","journal-title":"Leukemia"},{"issue":"11","key":"2019111808290905200_B18","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.3324\/haematol.13346","article-title":"Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.","volume":"93","author":"Passamonti","year":"2008","journal-title":"Haematologica"},{"issue":"4","key":"2019111808290905200_B19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ajh.21360","article-title":"Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy.","volume":"84","author":"Palandri","year":"2009","journal-title":"Am J Hematol"},{"issue":"4","key":"2019111808290905200_B20","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/leu.2010.5","article-title":"Leukocytosis is associated with poor survival but not with increased risk of thrombosis in essential thrombocythemia: a population-based study of 311 patients.","volume":"24","author":"Girodon","year":"2010","journal-title":"Leukemia"},{"issue":"10","key":"2019111808290905200_B21","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111808290905200_B22","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00277-009-0899-z","article-title":"A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkilating drugs.","volume":"89","author":"Cris\u00e0","year":"2010","journal-title":"Ann Hematol"},{"issue":"6","key":"2019111808290905200_B23","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.3324\/haematol.2009.019190","article-title":"Long-term follow-up of essential thrombocytemia in young adults: treatment strategies, major thrombotic complications and pregnancies outcomes. A study of 76 patients.","volume":"95","author":"Palandri","year":"2010","journal-title":"Haematologica"},{"issue":"5","key":"2019111808290905200_B24","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3324\/haematol.13869","article-title":"Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia.","volume":"94","author":"De Stefano","year":"2009","journal-title":"Haematologica"},{"issue":"3","key":"2019111808290905200_B25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1034\/j.1600-0609.2001.00367.x","article-title":"A single istitutional experience with 43 pregnancies in essential thrombocytemia.","volume":"66","author":"Wright","year":"2001","journal-title":"Eur J Haematol"},{"issue":"6","key":"2019111808290905200_B26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1600-0609.2004.00324.x","article-title":"Pregnancy in essential thrombocytaemia: experience with 40 pregnancies.","volume":"73","author":"Niittyvuopio","year":"2004","journal-title":"Eur J Haematol"},{"issue":"2","key":"2019111808290905200_B27","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1182\/blood-2007-01-071068","article-title":"Increased risk of pregnancy complications in patients with essential thrombocytemia carrying JAK2 (617V>F) mutation.","volume":"110","author":"Passamonti","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2019111808290905200_B28","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1600-0609.2009.01214.x","article-title":"Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies.","volume":"82","author":"Gangat","year":"2009","journal-title":"Eur J Haematol"},{"issue":"10","key":"2019111808290905200_B29","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/ajh.21504","article-title":"Outcome of 122 pregnancies in essential thrombocytemia patients. A report. from the Italian registry.","volume":"84","author":"Melillo","year":"2009","journal-title":"Am J Hematol"},{"issue":"1","key":"2019111808290905200_B30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3324\/haematol.2009.007542","article-title":"Hereditary thrombocytosis caused by MPL Ser505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis.","volume":"95","author":"Teofili","year":"2010","journal-title":"Haematologica"},{"issue":"20","key":"2019111808290905200_B31","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1200\/JCO.2002.11.507","article-title":"Overexpression of the polycythemia rubra vera-1 gene in essential thrombocythemia.","volume":"20","author":"Teofili","year":"2002","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111808290905200_B32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s004390050909","article-title":"A new assay for the analysis of X-chromosome inactivation based on methylation-specific PCR.","volume":"104","author":"Kubota","year":"1999","journal-title":"Hum Genet"},{"issue":"9464","key":"2019111808290905200_B33","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"5","key":"2019111808290905200_B34","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"issue":"9","key":"2019111808290905200_B35","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high risk polycythemia vera patients based on JAK2 (V617F) allele burden.","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"2019111808290905200_B36","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood.V90.4.1552","article-title":"A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype.","volume":"90","author":"Bernardi","year":"1997","journal-title":"Blood"},{"issue":"2","key":"2019111808290905200_B37","first-page":"143","article-title":"Treatment of polycythemia vera.","volume":"83","author":"Barbui","year":"1998","journal-title":"Haematologica"},{"issue":"2","key":"2019111808290905200_B38","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.","volume":"23","author":"Berk","year":"1986","journal-title":"Semin Hematol"},{"issue":"2","key":"2019111808290905200_B39","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"issue":"7","key":"2019111808290905200_B40","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3324\/haematol.13210","article-title":"A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis.","volume":"93","author":"Martini","year":"2008","journal-title":"Haematologica"},{"issue":"10","key":"2019111808290905200_B41","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2009.005918","article-title":"Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocytemia.","volume":"94","author":"Liu","year":"2009","journal-title":"Haematologica"},{"issue":"2","key":"2019111808290905200_B42","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1182\/blood-2005-06-2422","article-title":"Von Hippel-Lindau-dependent polycythemia is endemic on the island of Ischia: identification of a novel cluster.","volume":"107","author":"Perrotta","year":"2006","journal-title":"Blood"},{"issue":"9501","key":"2019111808290905200_B43","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"issue":"2","key":"2019111808290905200_B44","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/10428190802688152","article-title":"JAK2V617F mutation in essential thrombocytemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients.","volume":"50","author":"Palandri","year":"2009","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019111808290905200_B45","first-page":"215","article-title":"Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.","volume":"89","author":"Barbui","year":"2004","journal-title":"Haematologica"},{"key":"2019111808290905200_B46","article-title":"Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria [published online ahead of print, September 16, 2011].","author":"Finazzi","journal-title":"Leukemia"},{"issue":"8","key":"2019111808290905200_B47","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1182\/blood-2010-01-263319","article-title":"Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia.","volume":"116","author":"Alvarez-Larr\u00e1n","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2019111808290905200_B48","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.leukres.2008.06.006","article-title":"Is JAK2V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia.","volume":"33","author":"Dahabreh","year":"2009","journal-title":"Leuk Res"},{"issue":"9","key":"2019111808290905200_B49","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3324\/haematol.12970","article-title":"Effect of JAK2V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain.","volume":"93","author":"Ziakas","year":"2008","journal-title":"Haematologica"},{"issue":"2","key":"2019111808290905200_B50","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/HUMREP\/11.2.406","article-title":"A prospective study of early pregnancy loss.","volume":"11","author":"Ellish","year":"1996","journal-title":"Hum Reprod"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/10\/2219\/1349056\/zh801012002219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/10\/2219\/1349056\/zh801012002219.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T13:52:39Z","timestamp":1574085159000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/10\/2219\/29543\/Thrombocythemia-and-polycythemia-in-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,8]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,3,8]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-08-371328","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,8]]}}}